EA200702520A1 - Составы для изменения биофизических свойств слизистой оболочки - Google Patents

Составы для изменения биофизических свойств слизистой оболочки

Info

Publication number
EA200702520A1
EA200702520A1 EA200702520A EA200702520A EA200702520A1 EA 200702520 A1 EA200702520 A1 EA 200702520A1 EA 200702520 A EA200702520 A EA 200702520A EA 200702520 A EA200702520 A EA 200702520A EA 200702520 A1 EA200702520 A1 EA 200702520A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mucous
administered
formulation
biophysical properties
conductive
Prior art date
Application number
EA200702520A
Other languages
English (en)
Other versions
EA016072B1 (ru
Inventor
Вивик Ватанабе
Мэттью Томас
Джеффри Кэтстра
Роберт Кларк
Original Assignee
Палметрикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Палметрикс Инк. filed Critical Палметрикс Инк.
Publication of EA200702520A1 publication Critical patent/EA200702520A1/ru
Publication of EA016072B1 publication Critical patent/EA016072B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Были разработаны проводящие составы, содержащие проводящие агенты, такие как соли, ионные ПАВ или другие вещества в ионизированном состоянии или легко ионизирующиеся в среде водного или органического растворителя, и способы их применения. Один или более активных агентов, таких как противовирусные, антимикробные, противовоспалительные, белки или пептиды, могут быть включены в состав дополнительно. Активный агент может вводиться вместе с составом или включаться в состав, или может вводиться после введения проводящего состава. При нанесении на слизистые выстилающие жидкости состав изменяет биофизические свойства, такие как поверхностное натяжение, упругость поверхности и объемная вязкость слизистой оболочки. Состав вводится в количестве, достаточном для изменения биофизических свойств слизистых оболочек организма. Составы могут вводиться по нескольким различным назначениям: уменьшение распространения инфекционных заболеваний как бактериальных, так и вирусных, таких как ТОРС, грипп, туберкулез, а также RSV у людей и ящур у парнокопытных животных; минимизация загрязнения внешней среды вследствие образования частиц во время дыхания, кашля, чихания или речи, что особенно важно в применениях в чистой комнате; уменьшение или предотвращение появления обструктивного ночного апноэ и некоторых случаев синдрома раздраженной толстой кишки; а также контроль кинетики поглощения молекул препарата и патогенов.
EA200702520A 2005-05-18 2006-05-18 Применение состава соли кальция для изменения биофизических свойств слизистой оболочки EA016072B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68235605P 2005-05-18 2005-05-18
PCT/US2006/019443 WO2006125153A2 (en) 2005-05-18 2006-05-18 Formulations for alteration of biophysical properties of mucosal lining

Publications (2)

Publication Number Publication Date
EA200702520A1 true EA200702520A1 (ru) 2008-06-30
EA016072B1 EA016072B1 (ru) 2012-01-30

Family

ID=37401509

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702520A EA016072B1 (ru) 2005-05-18 2006-05-18 Применение состава соли кальция для изменения биофизических свойств слизистой оболочки

Country Status (13)

Country Link
US (2) US20070053844A1 (ru)
EP (3) EP2402001A1 (ru)
JP (2) JP2008540680A (ru)
KR (1) KR20080018872A (ru)
CN (2) CN102327285A (ru)
AU (1) AU2006247077A1 (ru)
BR (1) BRPI0609924A2 (ru)
CA (1) CA2608752A1 (ru)
EA (1) EA016072B1 (ru)
IL (1) IL187427A0 (ru)
NO (1) NO20076086L (ru)
NZ (2) NZ564110A (ru)
WO (1) WO2006125153A2 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
WO2010111680A2 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
KR20120002981A (ko) * 2009-03-26 2012-01-09 풀매트릭스 인코퍼레이티드 호흡기 감염 치료를 위한 약제 제형 및 방법
WO2010111650A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
AU2010229721A1 (en) * 2009-03-26 2011-10-06 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
EP2410984A2 (en) * 2009-03-26 2012-02-01 Pulmatrix, Inc. Anti-influenza formulations and methods
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
IL286573B (en) * 2010-09-29 2022-08-01 Pulmatrix Operating Co Inc Monovalent metallic cation dry powders for inhalation
ES2899621T3 (es) 2010-09-29 2022-03-14 Pulmatrix Operating Co Inc Polvos secos catiónicos que comprenden sal de magnesio
US20140336159A1 (en) 2011-10-07 2014-11-13 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
WO2013130767A1 (en) 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
MX2017005692A (es) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
EP3858440A3 (en) * 2015-11-18 2021-11-03 The Board of Trustees of the Leland Stanford Junior University B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components
CA3082871A1 (en) * 2018-01-11 2019-07-18 Emphysema Solutions Bv Compositions and methods for the treatment of lung emphysema and other forms of copd
US20220000909A1 (en) * 2018-11-29 2022-01-06 Yildiz Teknik Universitesi A nasal solution with closed basin natural spring water characteristic and method for obtaining said nasal solution
US20220051592A1 (en) * 2020-08-17 2022-02-17 Massachusetts Institute Of Technology Respiratory system simulator systems and methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3229179C2 (de) * 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
US4637815A (en) * 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5571535A (en) * 1990-11-30 1996-11-05 Flowers; Marianne Treatment of topical infections
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US5898037A (en) * 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
AUPM411494A0 (en) * 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
ATE218132T1 (de) * 1994-10-14 2002-06-15 Yamanouchi Pharma Co Ltd Azol-derivate
WO1996013254A1 (en) * 1994-10-26 1996-05-09 Glaxo Wellcome House Pharmaceutical composition comprising atovaquone
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
CA2327670A1 (en) * 1998-04-08 1999-10-14 Darrel Lavern Allen Pulmonary and nasal delivery of raloxifene
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
FR2780285B1 (fr) * 1998-06-29 2001-10-05 Goemar Lab Sa Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions
US6333051B1 (en) * 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
EP1173245B1 (en) * 1999-05-03 2004-09-01 Battelle Memorial Institute Compositions for aerosolization and inhalation
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
AU772096B2 (en) * 2000-03-14 2004-04-08 Sumika Enviro-Science Co., Ltd. Method for denaturing allergens
JP3481205B2 (ja) * 2000-11-24 2003-12-22 松下電器産業株式会社 インバータ制御用半導体装置および制御方法
CA2432319A1 (en) * 2000-12-21 2002-07-18 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030232019A1 (en) * 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
WO2003092654A1 (en) 2002-05-02 2003-11-13 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
US8003080B2 (en) * 2002-05-13 2011-08-23 Alexza Pharmaceuticals, Inc. Delivery of drug amines through an inhalation route
AU2003241477A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
US7534781B2 (en) * 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
JP2009514779A (ja) * 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
GB0324897D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
SE528121C2 (sv) * 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
CA2602596A1 (en) * 2004-03-30 2005-10-13 Malcolm King Compositions and methods for improved mucus function
JP2008507585A (ja) * 2004-07-26 2008-03-13 コセリックス インク 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療
US20070202051A1 (en) * 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
GB0818476D0 (en) * 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
EP2410984A2 (en) * 2009-03-26 2012-02-01 Pulmatrix, Inc. Anti-influenza formulations and methods

Also Published As

Publication number Publication date
WO2006125153A3 (en) 2008-02-28
KR20080018872A (ko) 2008-02-28
EA016072B1 (ru) 2012-01-30
JP2008540680A (ja) 2008-11-20
BRPI0609924A2 (pt) 2010-05-11
EP1906922A2 (en) 2008-04-09
EP2308469A1 (en) 2011-04-13
JP2012176990A (ja) 2012-09-13
EP2402001A1 (en) 2012-01-04
CA2608752A1 (en) 2006-11-23
NZ564110A (en) 2010-06-25
NO20076086L (no) 2008-02-14
CN102327285A (zh) 2012-01-25
WO2006125153A2 (en) 2006-11-23
IL187427A0 (en) 2011-08-01
US20150196589A1 (en) 2015-07-16
AU2006247077A1 (en) 2006-11-23
NZ593475A (en) 2012-12-21
CN101237853A (zh) 2008-08-06
US20070053844A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
EA200702520A1 (ru) Составы для изменения биофизических свойств слизистой оболочки
CY1122533T1 (el) Ανακινρα για χρηση στην αντιμετωπιση συνδρομου αποφρακτικης βρογχιολιτιδας
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
ME01458B (me) Kruta dozna forma koja sadrži inhibitor protonske pumpe i njena suspenzija
WO2005084638A3 (en) Formulations decreasing infectivity of pulmonary diseases
ATE462410T1 (de) Selbstemulgierendes butylbenzolphthalein- arzneimittelabgabesystem, sein herstellungsverfahren und seine anwendung
JP2009503097A5 (ru)
JP2013536874A (ja) 鼻腔噴霧剤
WO2003075968A3 (en) Biocompatible hydrophilic films from polymeric mini-emulsions for application to skin
JP2006516272A5 (ru)
NZ597657A (en) Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections
AR043536A1 (es) Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico
BR0102940A (pt) Agente para o tratamento de doença de parkinson compreendendo um agente de melhora da função de astrócitos como ingrediente ativo
RU2006109966A (ru) Препарат "янтастим-с" для терапии и профилактики инфекционных заболеваний животных
ATE438684T1 (de) Thermoplastische filme und herstellungsverfahren dafür
ATE355833T1 (de) Pharmazeutische polymerformulierung zur retardierten freisetzung von terbutalinsulfat
CN103933309A (zh) 用吸入雾化的紫蒜液方法治疗肺结核
JPH0232013A (ja) 点鼻剤
JP7169017B2 (ja) 睡眠環境改善方法
JP2010260855A (ja) 気道異物除去剤及び気道異物除去用組成物
EP1758922B8 (en) Peptide substance restoring function of respiratory organs
BRPI0414223A (pt) uso de extratos de gentiana lutea como um agente antimicrobiano
BR0317292A (pt) Derivados de amida de ácido antranìlico e seu uso farmacêutico
RU2217159C1 (ru) Раствор для ингаляций фармацевтической композиции глутовент и способ его терапевтического применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ RU